INFLAMASE FORTE Drug Patent Profile
✉ Email this page to a colleague
When do Inflamase Forte patents expire, and what generic alternatives are available?
Inflamase Forte is a drug marketed by Novartis and is included in one NDA.
The generic ingredient in INFLAMASE FORTE is prednisolone sodium phosphate. There are eighty-eight drug master file entries for this compound. Fifteen suppliers are listed for this compound. Additional details are available on the prednisolone sodium phosphate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Inflamase Forte
A generic version of INFLAMASE FORTE was approved as prednisolone sodium phosphate by BAUSCH AND LOMB on July 29th, 1994.
Summary for INFLAMASE FORTE
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 36 |
Patent Applications: | 4,891 |
Formulation / Manufacturing: | see details |
DailyMed Link: | INFLAMASE FORTE at DailyMed |
Anatomical Therapeutic Chemical (ATC) Classes for INFLAMASE FORTE
US Patents and Regulatory Information for INFLAMASE FORTE
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Novartis | INFLAMASE FORTE | prednisolone sodium phosphate | SOLUTION/DROPS;OPHTHALMIC | 080751-002 | Approved Prior to Jan 1, 1982 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |